Global Anti-rheumatic Market is valued at US$ 62.97 Billion in 2022 and it is expected to reach US$ 76.13 Billion by 2029 with a CAGR of 2.75% over the forecast period.
Global Anti-rheumatic Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Increasing prevalence of rheumatoid arthritis, rising geriatric population and growing number of product approvals for the treatment of rheumatoid arthritis are major factors anticipated to drive the growth of the Global Anti-rheumatic Market for the Forecast Period.
The drugs which are used to treat rheumatoid arthritis are called as antirheumatic drugs. Rheumatoid arthritis is an advanced form of arthritis that has disturbing effects on joints and general health. Rheumatoid arthritis is auto-immune disease, and symptoms include fatigue, joint pain, swollen joints, fever, and loss of appetite. The different classes of antirheumatic drugs include nonsteroidal anti-inflammatory drugs, corticosteroids, disease modifying anti-rheumatic drugs (DMARDs), slow-acting antirheumatic drugs (SAARDs), immunosuppressive cytotoxic drugs. The antirheumatic dugs are used for reducing pain, swelling preventing joint damage and slowing the development of arthritis.
The covid-19 pandemic has shown a negative impact on global anti-rheumatic market. The lockdown and quarantine affected the availability of raw materials needed for the manufacturing of antirheumatic medications. The healthcare focus on treatment and diagnosis of Covid-19 patients paused or postponed treatment of arthritis patients.
The global anti-rheumatic market is segmented into type, drug class, distribution channel and region & country level. On the basis of type the global anti-rheumatic market is segmented into prescription and over the counter. On the basis of drug class, the market is segmented into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and other. On the basis of distribution channel, the global anti-rheumatic market is segmented into hospitals pharmacies, retail pharmacies, e-commerce and others.
The regions covered in global anti-rheumatic market report are North America, Europe, Asia-Pacific, Latin America, and Rest of the World. Based on country level, the market of global anti-rheumatic market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, Southeast Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some of the key players for global antirheumatic market are -
One of the major factors driving the growth of the global anti-rheumatic market increasing prevalence of rheumatoid arthritis. For instance; Arthritis is a common health problem in the global population, affecting more than 350 million people and a leading cause of disability. Hence, the increasing prevalence of rheumatoid arthritis one of the main factors driving the demand for anti-rheumatics globally.
In addition, another factor expected to drive the growth of global anti-rheumatic market is rising number of geriatric populations. The geriatric population has more risk of developing rheumatoid arthritis which will further increase the market growth of the global antirheumatic market. For instance; as per World Health Organization (WHO) the number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.
Moreover, growing number of product approvals and technological advancements in antirheumatic drugs are also boosting the market growth. For instance; as per new published on October 31st, 2018; Sandoz's Biosimilar Adalimumab, Hyrimoz approved by U.S Food and Drug Administration to treat rheumatoid arthritis and other arthritis types.
However, the side effects associated with antirheumatic drugs restraining the market growth. In spite of that, increasing adoption of advanced technologies may provide more opportunities for the further growth of global anti-rheumatic market for the forecast period.
The North America is expected to dominate the global anti-rheumatic market due to rising awareness, increasing incidences of rheumatoid arthritis and research and developments in treatment for rheumatoid arthritis and growing healthcare expenditure. Increasing awareness amongst people and availability of effective treatments in the North America region is expected to drive the market growth of global anti-rheumatic market.
In addition, increasing incidences rheumatoid arthritis is also adding growth to the market in this region. For example; nearly 1.5 million Americans have rheumatoid arthritis every year as per Healthline rheumatoid arthritis facts. Moreover, research and developments for the treatment for rheumatoid arthritis. For example; new indication for Ruxience Pfizer's biosimilar for Genentech and Biogen's Rituxan (rituximab) was approved by U.S Food and Drug Administration. Furthermore, the growing expenditure from the governments is further likely to drive the growth of the antirheumatic market in the North America region.
Asia Pacific is anticipated to be fastest growing region for the global anti-rheumatic market due to rising geriatric population, increasing awareness about rheumatoid arthritis treatments, and developing healthcare infrastructure of emerging countries such as China and India. For instance; India’s ageing population is projected to rise from 60 million to 227 million by 2050 as per the World Health Organization.
Riabni, the Biosimilar to Rituxan Approved by FDA
On June 8th, 2022; The biosimilar of Riabni, Rituxan approved by U.S Food and Drug Administration for the treatment of Rheumatoid Arthritis for adults with moderate to severe RA announced by Amgen. RIABNI is previously approved for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) Microscopic Polyangiitis (MPA)and Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL).
Cumberland Pharmaceuticals Launched RediTrex Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis
On September 29th, 2021; Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the national launch of its RediTrex (methotrexate) line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.
FDA Approved Upadacitinib for Moderate to Severe Rheumatoid Arthritis
On August 20th, 2019; a Janus kinase (JAK) inhibitor drug for moderate to severe Rheumatoid Arthritis was approved by the U.S. Food and Drug Administration (FDA). Upadacitinib was approved for adults suffering from rheumatoid arthritis with moderate to severe and dose of the tablet approved was 15 mg of RINVOQ™ (upadacitinib) once-daily oral.
|2016 - 2021
|2022 - 2029
|Market Size in 2022:
|USD 62.97 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2029:
|USD 76.13 Billion
|Tables, Charts & Figures:
|Cumberland Pharmaceuticals Inc. AbbVie Inc., AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol, Myers Squibb Company, Celltrion Inc., Eli Lilly and F. Hoffmann. and others
|By Type, By Drug Type, By Distribution Channel
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®